Lupin shares hit a fresh 52-week high at Rs 2,284.15 today after the company announced the launch of Mirabegron Extended-Release Tablets, 50 mg, in the United States, after U.S. FDA approval.
In the exchange filing, the company shared, “Mirabegron Extended-Release Tablets, 50 mg is a generic equivalent of Myrbetriq® Extended-Release Tablets, 50 mg of Astellas Pharma Global Development, Inc.
Mirabegron Extended-Release Tablets, 50 mg had estimated annual sales of USD 1,600 million in the U.S. (IQVIA MAT July 2024).”
The share price opened at ₹2,225.00. The share reached a day high of ₹2,284.15 and a low of ₹2,206.60. The company’s market capitalization has reached ₹1,03,924.07 crore. Lupin shares reached its 52-week high on 04-Sep-2024 at Rs 2,284.15 and its 52-week low on 22-Sep-2023 at Rs 1,091.50.
